Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Rilematovir in Healthy Japanese Adults
NCT02398591Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 8 more. Started Apr 2015; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02398591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398591.